Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIR Inhaled Insulin Dosing Algorithms in T2DM
NCT00391209Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of AIR Inhaled Insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Glycemic control similar to a more aggressive approach at 6 months. Started Oct 2006; status: completed.
02
Drugs
AIR Inhaled Insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00391209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391209.